Scholarlink

Background <p>Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease with incompletely understood aetiology beyond the HLA-DRB1 locus. Mitochondrial haplogroup U, prevalent in Middle Eastern and Near Eastern populations, encodes functional variants in NADH dehydrogenase subunits associated with elevated reactive oxygen species (ROS) production. A 2022 study (Al-Kafaji et al., PLoS ONE) reported a nominal association between haplogroup U and RRMS in Saudi Arab patients (OR 6.26; 95% CI 0.82–48.10) in a single, small (<i>n</i> = 47) cohort. We conducted a systematic review and meta-analysis to determine whether this signal is supported by independently verifiable case-control data from other Arab or Near Eastern populations.</p> Methods <p>PRISMA 2020 systematic review. PubMed/MEDLINE was searched to 15 July 2026 using a concept-level strategy – (“mitochondrial DNA”[tiab] OR “mtDNA”[tiab] OR “DNA, Mitochondrial”[MeSH] OR “Mitochondria”[MeSH]) AND (“haplogroup”[tiab] OR “haplogroups”[tiab] OR “haplotype”[tiab]) AND (“multiple sclerosis”[tiab] OR “Multiple Sclerosis”[MeSH] OR “demyelinating”[tiab] OR “RRMS”[tiab]) – with no population terms applied at the search stage; population eligibility (Arab or Near Eastern cohort) was assessed during screening rather than baked into the search string, to maximise sensitivity. Eligible studies were case-control studies reporting mitochondrial haplogroup U frequency in MS cases versus healthy controls in an Arab or Near Eastern population, with data sufficient to construct a 2 × 2 table. Odds ratios were pooled using a fixed-effect inverse-variance model.</p> Results <p>The search identified 30 records. After screening and full-text assessment, two studies met full inclusion criteria for quantitative pooling: Al-Kafaji et al. [1] (Saudi Arabia, <i>n</i> = 47) and Hassani-Kumleh et al. [2] (Iran, <i>n</i> = 154); total pooled <i>N</i> = 201 (77 MS cases, 124 controls). The fixed-effect pooled OR was 4.11 (95% CI 1.25–13.55; <i>p</i> = 0.020), with no meaningful heterogeneity (I²=0%, Cochran’s Q = 0.25, df = 1). Two further Near Eastern studies (Houshmand et al. [3]; Ghabaee et al. [4]) reported related but non-poolable data – haplogroup J association and a haplogroup U case-series prevalence without a control arm, respectively – and are discussed narratively.</p> Conclusions <p>Across two independently verified Near Eastern case-control cohorts, mitochondrial haplogroup U is significantly associated with increased MS risk (pooled OR 4.11, 95% CI 1.25–13.55). The evidence base remains small, and the wide confidence interval reflects this. A larger, prospective, adequately powered study in Arab and Near Eastern MS cohorts is needed to confirm and refine this association.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mitochondrial Haplogroup U and multiple sclerosis risk in Arab and Near Eastern populations: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Ibrahim Ibrahim Shuaibu

摘要

Background

Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease with incompletely understood aetiology beyond the HLA-DRB1 locus. Mitochondrial haplogroup U, prevalent in Middle Eastern and Near Eastern populations, encodes functional variants in NADH dehydrogenase subunits associated with elevated reactive oxygen species (ROS) production. A 2022 study (Al-Kafaji et al., PLoS ONE) reported a nominal association between haplogroup U and RRMS in Saudi Arab patients (OR 6.26; 95% CI 0.82–48.10) in a single, small (n = 47) cohort. We conducted a systematic review and meta-analysis to determine whether this signal is supported by independently verifiable case-control data from other Arab or Near Eastern populations.

Methods

PRISMA 2020 systematic review. PubMed/MEDLINE was searched to 15 July 2026 using a concept-level strategy – (“mitochondrial DNA”[tiab] OR “mtDNA”[tiab] OR “DNA, Mitochondrial”[MeSH] OR “Mitochondria”[MeSH]) AND (“haplogroup”[tiab] OR “haplogroups”[tiab] OR “haplotype”[tiab]) AND (“multiple sclerosis”[tiab] OR “Multiple Sclerosis”[MeSH] OR “demyelinating”[tiab] OR “RRMS”[tiab]) – with no population terms applied at the search stage; population eligibility (Arab or Near Eastern cohort) was assessed during screening rather than baked into the search string, to maximise sensitivity. Eligible studies were case-control studies reporting mitochondrial haplogroup U frequency in MS cases versus healthy controls in an Arab or Near Eastern population, with data sufficient to construct a 2 × 2 table. Odds ratios were pooled using a fixed-effect inverse-variance model.

Results

The search identified 30 records. After screening and full-text assessment, two studies met full inclusion criteria for quantitative pooling: Al-Kafaji et al. [1] (Saudi Arabia, n = 47) and Hassani-Kumleh et al. [2] (Iran, n = 154); total pooled N = 201 (77 MS cases, 124 controls). The fixed-effect pooled OR was 4.11 (95% CI 1.25–13.55; p = 0.020), with no meaningful heterogeneity (I²=0%, Cochran’s Q = 0.25, df = 1). Two further Near Eastern studies (Houshmand et al. [3]; Ghabaee et al. [4]) reported related but non-poolable data – haplogroup J association and a haplogroup U case-series prevalence without a control arm, respectively – and are discussed narratively.

Conclusions

Across two independently verified Near Eastern case-control cohorts, mitochondrial haplogroup U is significantly associated with increased MS risk (pooled OR 4.11, 95% CI 1.25–13.55). The evidence base remains small, and the wide confidence interval reflects this. A larger, prospective, adequately powered study in Arab and Near Eastern MS cohorts is needed to confirm and refine this association.